Differential cardiovascular effects of synthetic peptides derived from endomorphin-1 in anesthetized rats.
Previously, five synthetic peptides derived from endomorphin-1 (Tyr1-Pro2-Trp3-Phe4-NH2, EM-1), including Tyr-D-Ala-Trp-p-Cl-Phe-NH2 (HDAPC), Tyr-D-Ala-Trp-Phe-NH2 (HDADC), Nalpha-amidino-Tyr-D-Ala-Trp-p-Cl-Phe-NH2 (GDAPC), Nalpha-amidino-Tyr-D-Ala-Trp-Phe-NH2 (GDADC) and Nalpha-amidino-Tyr-D-Pro-Gly-Trp-p-Cl-Phe-NH2 (GBDPC), were described to elicit analgesia by subcutaneous administration with enhanced metabolic stabilities. To further our knowledge of the influences of particular modification on the pharmacological activities of EM-1, the present study was undertaken to investigate cardiovascular effects of these peptides in anesthetized rats by intravenous injection. Our results showed that the four D-Ala-containing peptides decreased the systemic arterial pressure (SAP) and heart rate (HR) through a naloxone-sensitive mechanism. Different patterns, potencies and durations of cardiovascular effects were observed among these peptides. When compared to EM-1, the hemodynamic responses to these four tetrapeptides were significantly lower in magnitude but much longer in duration. Surprisingly, intravenous administration of the only pentapeptide GBDPC produced fairly prolonged hypertensive and tachycardiac effects, which was naloxone-insensitive, thus providing evidence that changes in the primary structure of a peptide can profoundly affect its pharmacological activity. Comparisons of the cardiovascular effects between these peptides showed that each modification introduced into EM-1, including N-amidination, chloro-halogenation and unnatural amino acid substitution, played a role in the influence on the cardiovascular regulation of these peptides.
Liu
Hongmei
H
State Key Laboratory of Chinese Medicine and Molecular Pharmacology, Department of Applied Biology and Chemical Technology, The Hong Kong Polytechnic University, Kowloon, HKSAR, Hong Kong.
Yang
Yang
Y
Xin
Ruihua
R
Liu
Xing
X
Cao
Yiming
Y
Ni
Jingman
J
Wang
Rui
R
D000701:Analgesics, Opioid / Q000008:administration & dosage / Q000494:pharmacology*; D000818:Animals; D001794:Blood Pressure / Q000187:drug effects; D002319:Cardiovascular System / Q000187:drug effects*; D006339:Heart Rate / Q000187:drug effects; D007275:Injections, Intravenous; D008297:Male; D009842:Oligopeptides / Q000737:chemistry*; D018847:Opioid Peptides / Q000138:chemical synthesis* / Q000737:chemistry / Q000494:pharmacology*; D010455:Peptides / Q000494:pharmacology; D051381:Rats; D017208:Rats, Wistar
D000701:Analgesics, Opioid; D009842:Oligopeptides; D018847:Opioid Peptides; D010455:Peptides; C105293:endomorphin 1